Geriatric 8 screening of frailty in patients with prostate cancer
Objectives To evaluate the association between the score of the Geriatric 8 screening tool and treatment by disease stages in patients with prostate cancer. Methods Between January 2017 and June 2019, we prospectively evaluated the Geriatric 8 in 540 prostate cancer patients who were treated with ro...
Gespeichert in:
| Veröffentlicht in: | International journal of urology 2020-08, Vol.27 (8), p.642-648 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 648 |
|---|---|
| container_issue | 8 |
| container_start_page | 642 |
| container_title | International journal of urology |
| container_volume | 27 |
| creator | Momota, Masaki Hatakeyama, Shingo Soma, Osamu Tanaka, Toshikazu Hamano, Itsuto Fujita, Naoki Okamoto, Teppei Yoneyama, Tohru Yamamoto, Hayato Imai, Atsushi Yoshikawa, Kazuaki Yoneyama, Takahiro Hashimoto, Yasuhiro Ohyama, Chikara |
| description | Objectives
To evaluate the association between the score of the Geriatric 8 screening tool and treatment by disease stages in patients with prostate cancer.
Methods
Between January 2017 and June 2019, we prospectively evaluated the Geriatric 8 in 540 prostate cancer patients who were treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and standard of care for metastatic hormone‐naïve prostate cancer or castration‐resistant prostate cancer. The primary purpose was the association between frailty (Geriatric 8 ≤14) and robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone, and metastatic diseases. Secondary purposes included a comparison of the Geriatric 8 scores among the disease status and the influence of Geriatric 8 score on overall survival.
Results
The median age was 75 years. Geriatric 8 scores ≤14 were seen in 36% of robot‐assisted radical prostatectomy (n = 78/214), 57% of radiotherapy (n = 119/209), 91% of androgen deprivation therapy alone (n = 19/21) and 70% of metastatic diseases (n = 67/96). The median Geriatric 8 score in patients treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and metastatic diseases was 15.0, 14.0, 12.0 and 12.8, respectively. The median Geriatric 8 score was significantly higher in the metastatic disease than that in localized disease (14.5 vs 12.8, respectively). Robot‐assisted radical prostatectomy patients had a significantly higher Geriatric 8 score than radiotherapy patients, with the cut‐off value of 13 in metastatic hormone‐naïve prostate cancer patients, and between Geriatric 8 scores ≤12 and >12 in castration‐resistant prostate cancer patients.
Conclusion
The Geriatric 8 score is significantly associated with treatment by disease stages in patients with prostate cancer. |
| doi_str_mv | 10.1111/iju.14256 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2410358151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2430186838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4616-4ed70186ff7a2c286f2a9c3d4a3ac38bcfc3cc8c6daf90e198b6d75665fccbc3</originalsourceid><addsrcrecordid>eNp10L1OwzAUBWALgWgpDLwAisQCQ6j_4jgjVFCKKrGUOXJubHCVJsVOVPVteBaeDJcUBiS82MOn43sPQucE35BwxnbZ3RBOE3GAhoRzGlPM6SEa4oxksSQpHaAT75cYE0aJPEYDRhOMBSVDdDfVzqrWWfj8kJEHp3Vt69eoMZFxylbtNrJ1tFat1XXro41t36K1a3yrWh2BqkG7U3RkVOX12f4eocXD_WLyGM-fp7PJ7TwGLoiIuS5TTKQwJlUUaHhQlQEruWIKmCzAAAOQIEplMqxJJgtRpokQiQEogI3QVR8bvn_vtG_zlfWgq0rVuul8TjnBLJEkIYFe_qHLpnN1GC4othtCMhnUda8g7OOdNvna2ZVy25zgfNdrHnrNv3sN9mKf2BUrXf7KnyIDGPdgYyu9_T8pnz299JFfuQGCNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2430186838</pqid></control><display><type>article</type><title>Geriatric 8 screening of frailty in patients with prostate cancer</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Momota, Masaki ; Hatakeyama, Shingo ; Soma, Osamu ; Tanaka, Toshikazu ; Hamano, Itsuto ; Fujita, Naoki ; Okamoto, Teppei ; Yoneyama, Tohru ; Yamamoto, Hayato ; Imai, Atsushi ; Yoshikawa, Kazuaki ; Yoneyama, Takahiro ; Hashimoto, Yasuhiro ; Ohyama, Chikara</creator><creatorcontrib>Momota, Masaki ; Hatakeyama, Shingo ; Soma, Osamu ; Tanaka, Toshikazu ; Hamano, Itsuto ; Fujita, Naoki ; Okamoto, Teppei ; Yoneyama, Tohru ; Yamamoto, Hayato ; Imai, Atsushi ; Yoshikawa, Kazuaki ; Yoneyama, Takahiro ; Hashimoto, Yasuhiro ; Ohyama, Chikara</creatorcontrib><description>Objectives
To evaluate the association between the score of the Geriatric 8 screening tool and treatment by disease stages in patients with prostate cancer.
Methods
Between January 2017 and June 2019, we prospectively evaluated the Geriatric 8 in 540 prostate cancer patients who were treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and standard of care for metastatic hormone‐naïve prostate cancer or castration‐resistant prostate cancer. The primary purpose was the association between frailty (Geriatric 8 ≤14) and robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone, and metastatic diseases. Secondary purposes included a comparison of the Geriatric 8 scores among the disease status and the influence of Geriatric 8 score on overall survival.
Results
The median age was 75 years. Geriatric 8 scores ≤14 were seen in 36% of robot‐assisted radical prostatectomy (n = 78/214), 57% of radiotherapy (n = 119/209), 91% of androgen deprivation therapy alone (n = 19/21) and 70% of metastatic diseases (n = 67/96). The median Geriatric 8 score in patients treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and metastatic diseases was 15.0, 14.0, 12.0 and 12.8, respectively. The median Geriatric 8 score was significantly higher in the metastatic disease than that in localized disease (14.5 vs 12.8, respectively). Robot‐assisted radical prostatectomy patients had a significantly higher Geriatric 8 score than radiotherapy patients, with the cut‐off value of <14.5. The overall survival was significantly different between Geriatric 8 scores ≤13 and >13 in metastatic hormone‐naïve prostate cancer patients, and between Geriatric 8 scores ≤12 and >12 in castration‐resistant prostate cancer patients.
Conclusion
The Geriatric 8 score is significantly associated with treatment by disease stages in patients with prostate cancer.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/iju.14256</identifier><identifier>PMID: 32500621</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Aged ; Androgen Antagonists - therapeutic use ; Androgens ; Cancer surgery ; Castration ; Disease ; Early Detection of Cancer ; frailty ; Frailty - diagnosis ; geriatric screening ; Geriatrics ; Geriatric 8 ; Humans ; Male ; Metastases ; Metastasis ; prognosis ; Prostate cancer ; Prostatectomy ; Prostatic Neoplasms - surgery ; Radiation therapy ; Robots ; Survival</subject><ispartof>International journal of urology, 2020-08, Vol.27 (8), p.642-648</ispartof><rights>2020 The Japanese Urological Association</rights><rights>2020 The Japanese Urological Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4616-4ed70186ff7a2c286f2a9c3d4a3ac38bcfc3cc8c6daf90e198b6d75665fccbc3</citedby><cites>FETCH-LOGICAL-c4616-4ed70186ff7a2c286f2a9c3d4a3ac38bcfc3cc8c6daf90e198b6d75665fccbc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fiju.14256$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fiju.14256$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32500621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Momota, Masaki</creatorcontrib><creatorcontrib>Hatakeyama, Shingo</creatorcontrib><creatorcontrib>Soma, Osamu</creatorcontrib><creatorcontrib>Tanaka, Toshikazu</creatorcontrib><creatorcontrib>Hamano, Itsuto</creatorcontrib><creatorcontrib>Fujita, Naoki</creatorcontrib><creatorcontrib>Okamoto, Teppei</creatorcontrib><creatorcontrib>Yoneyama, Tohru</creatorcontrib><creatorcontrib>Yamamoto, Hayato</creatorcontrib><creatorcontrib>Imai, Atsushi</creatorcontrib><creatorcontrib>Yoshikawa, Kazuaki</creatorcontrib><creatorcontrib>Yoneyama, Takahiro</creatorcontrib><creatorcontrib>Hashimoto, Yasuhiro</creatorcontrib><creatorcontrib>Ohyama, Chikara</creatorcontrib><title>Geriatric 8 screening of frailty in patients with prostate cancer</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>Objectives
To evaluate the association between the score of the Geriatric 8 screening tool and treatment by disease stages in patients with prostate cancer.
Methods
Between January 2017 and June 2019, we prospectively evaluated the Geriatric 8 in 540 prostate cancer patients who were treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and standard of care for metastatic hormone‐naïve prostate cancer or castration‐resistant prostate cancer. The primary purpose was the association between frailty (Geriatric 8 ≤14) and robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone, and metastatic diseases. Secondary purposes included a comparison of the Geriatric 8 scores among the disease status and the influence of Geriatric 8 score on overall survival.
Results
The median age was 75 years. Geriatric 8 scores ≤14 were seen in 36% of robot‐assisted radical prostatectomy (n = 78/214), 57% of radiotherapy (n = 119/209), 91% of androgen deprivation therapy alone (n = 19/21) and 70% of metastatic diseases (n = 67/96). The median Geriatric 8 score in patients treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and metastatic diseases was 15.0, 14.0, 12.0 and 12.8, respectively. The median Geriatric 8 score was significantly higher in the metastatic disease than that in localized disease (14.5 vs 12.8, respectively). Robot‐assisted radical prostatectomy patients had a significantly higher Geriatric 8 score than radiotherapy patients, with the cut‐off value of <14.5. The overall survival was significantly different between Geriatric 8 scores ≤13 and >13 in metastatic hormone‐naïve prostate cancer patients, and between Geriatric 8 scores ≤12 and >12 in castration‐resistant prostate cancer patients.
Conclusion
The Geriatric 8 score is significantly associated with treatment by disease stages in patients with prostate cancer.</description><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Androgens</subject><subject>Cancer surgery</subject><subject>Castration</subject><subject>Disease</subject><subject>Early Detection of Cancer</subject><subject>frailty</subject><subject>Frailty - diagnosis</subject><subject>geriatric screening</subject><subject>Geriatrics</subject><subject>Geriatric 8</subject><subject>Humans</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>prognosis</subject><subject>Prostate cancer</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Radiation therapy</subject><subject>Robots</subject><subject>Survival</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L1OwzAUBWALgWgpDLwAisQCQ6j_4jgjVFCKKrGUOXJubHCVJsVOVPVteBaeDJcUBiS82MOn43sPQucE35BwxnbZ3RBOE3GAhoRzGlPM6SEa4oxksSQpHaAT75cYE0aJPEYDRhOMBSVDdDfVzqrWWfj8kJEHp3Vt69eoMZFxylbtNrJ1tFat1XXro41t36K1a3yrWh2BqkG7U3RkVOX12f4eocXD_WLyGM-fp7PJ7TwGLoiIuS5TTKQwJlUUaHhQlQEruWIKmCzAAAOQIEplMqxJJgtRpokQiQEogI3QVR8bvn_vtG_zlfWgq0rVuul8TjnBLJEkIYFe_qHLpnN1GC4othtCMhnUda8g7OOdNvna2ZVy25zgfNdrHnrNv3sN9mKf2BUrXf7KnyIDGPdgYyu9_T8pnz299JFfuQGCNQ</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Momota, Masaki</creator><creator>Hatakeyama, Shingo</creator><creator>Soma, Osamu</creator><creator>Tanaka, Toshikazu</creator><creator>Hamano, Itsuto</creator><creator>Fujita, Naoki</creator><creator>Okamoto, Teppei</creator><creator>Yoneyama, Tohru</creator><creator>Yamamoto, Hayato</creator><creator>Imai, Atsushi</creator><creator>Yoshikawa, Kazuaki</creator><creator>Yoneyama, Takahiro</creator><creator>Hashimoto, Yasuhiro</creator><creator>Ohyama, Chikara</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>202008</creationdate><title>Geriatric 8 screening of frailty in patients with prostate cancer</title><author>Momota, Masaki ; Hatakeyama, Shingo ; Soma, Osamu ; Tanaka, Toshikazu ; Hamano, Itsuto ; Fujita, Naoki ; Okamoto, Teppei ; Yoneyama, Tohru ; Yamamoto, Hayato ; Imai, Atsushi ; Yoshikawa, Kazuaki ; Yoneyama, Takahiro ; Hashimoto, Yasuhiro ; Ohyama, Chikara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4616-4ed70186ff7a2c286f2a9c3d4a3ac38bcfc3cc8c6daf90e198b6d75665fccbc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Androgens</topic><topic>Cancer surgery</topic><topic>Castration</topic><topic>Disease</topic><topic>Early Detection of Cancer</topic><topic>frailty</topic><topic>Frailty - diagnosis</topic><topic>geriatric screening</topic><topic>Geriatrics</topic><topic>Geriatric 8</topic><topic>Humans</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>prognosis</topic><topic>Prostate cancer</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Radiation therapy</topic><topic>Robots</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Momota, Masaki</creatorcontrib><creatorcontrib>Hatakeyama, Shingo</creatorcontrib><creatorcontrib>Soma, Osamu</creatorcontrib><creatorcontrib>Tanaka, Toshikazu</creatorcontrib><creatorcontrib>Hamano, Itsuto</creatorcontrib><creatorcontrib>Fujita, Naoki</creatorcontrib><creatorcontrib>Okamoto, Teppei</creatorcontrib><creatorcontrib>Yoneyama, Tohru</creatorcontrib><creatorcontrib>Yamamoto, Hayato</creatorcontrib><creatorcontrib>Imai, Atsushi</creatorcontrib><creatorcontrib>Yoshikawa, Kazuaki</creatorcontrib><creatorcontrib>Yoneyama, Takahiro</creatorcontrib><creatorcontrib>Hashimoto, Yasuhiro</creatorcontrib><creatorcontrib>Ohyama, Chikara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Momota, Masaki</au><au>Hatakeyama, Shingo</au><au>Soma, Osamu</au><au>Tanaka, Toshikazu</au><au>Hamano, Itsuto</au><au>Fujita, Naoki</au><au>Okamoto, Teppei</au><au>Yoneyama, Tohru</au><au>Yamamoto, Hayato</au><au>Imai, Atsushi</au><au>Yoshikawa, Kazuaki</au><au>Yoneyama, Takahiro</au><au>Hashimoto, Yasuhiro</au><au>Ohyama, Chikara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Geriatric 8 screening of frailty in patients with prostate cancer</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2020-08</date><risdate>2020</risdate><volume>27</volume><issue>8</issue><spage>642</spage><epage>648</epage><pages>642-648</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>Objectives
To evaluate the association between the score of the Geriatric 8 screening tool and treatment by disease stages in patients with prostate cancer.
Methods
Between January 2017 and June 2019, we prospectively evaluated the Geriatric 8 in 540 prostate cancer patients who were treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and standard of care for metastatic hormone‐naïve prostate cancer or castration‐resistant prostate cancer. The primary purpose was the association between frailty (Geriatric 8 ≤14) and robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone, and metastatic diseases. Secondary purposes included a comparison of the Geriatric 8 scores among the disease status and the influence of Geriatric 8 score on overall survival.
Results
The median age was 75 years. Geriatric 8 scores ≤14 were seen in 36% of robot‐assisted radical prostatectomy (n = 78/214), 57% of radiotherapy (n = 119/209), 91% of androgen deprivation therapy alone (n = 19/21) and 70% of metastatic diseases (n = 67/96). The median Geriatric 8 score in patients treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and metastatic diseases was 15.0, 14.0, 12.0 and 12.8, respectively. The median Geriatric 8 score was significantly higher in the metastatic disease than that in localized disease (14.5 vs 12.8, respectively). Robot‐assisted radical prostatectomy patients had a significantly higher Geriatric 8 score than radiotherapy patients, with the cut‐off value of <14.5. The overall survival was significantly different between Geriatric 8 scores ≤13 and >13 in metastatic hormone‐naïve prostate cancer patients, and between Geriatric 8 scores ≤12 and >12 in castration‐resistant prostate cancer patients.
Conclusion
The Geriatric 8 score is significantly associated with treatment by disease stages in patients with prostate cancer.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32500621</pmid><doi>10.1111/iju.14256</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-8172 |
| ispartof | International journal of urology, 2020-08, Vol.27 (8), p.642-648 |
| issn | 0919-8172 1442-2042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2410358151 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Aged Androgen Antagonists - therapeutic use Androgens Cancer surgery Castration Disease Early Detection of Cancer frailty Frailty - diagnosis geriatric screening Geriatrics Geriatric 8 Humans Male Metastases Metastasis prognosis Prostate cancer Prostatectomy Prostatic Neoplasms - surgery Radiation therapy Robots Survival |
| title | Geriatric 8 screening of frailty in patients with prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T19%3A39%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Geriatric%C2%A08%20screening%20of%20frailty%20in%20patients%20with%20prostate%20cancer&rft.jtitle=International%20journal%20of%20urology&rft.au=Momota,%20Masaki&rft.date=2020-08&rft.volume=27&rft.issue=8&rft.spage=642&rft.epage=648&rft.pages=642-648&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/iju.14256&rft_dat=%3Cproquest_cross%3E2430186838%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2430186838&rft_id=info:pmid/32500621&rfr_iscdi=true |